Goodwin Procter LLP advised CRISPR Therapeutics on the deal. CRISPR Therapeutics (NASDAQ: CRSP) announced its collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) to develop, manufacture, and...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Vaccitech on the deal. Vaccitech announced the completion of its $168 million Series B, including the conversion of $43 million in convertible loan...
You must be a Standard 1 Year member to access this content.
Goodwin Procter LLP advised Monte Rosa Therapeutics on the deal. Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing...
You must be a Standard 1 Year member to access this content.
